Laboratory Corp of America Holdings (LH)

HEALTH CARE: HEALTH CARE SERVICES
SIC: SERVICES-MEDICAL LABORATORIES

358 S MAIN ST BURLINGTON, NC 27215

Laboratory Corporation of America is a holding company. Co. provides clinical laboratory tests used in routine testing, patient diagnosis, and in the monitoring and treatment of disease. Co. also provides specialty testing services in the areas of allergy, clinical trials, diagnostic genetics, identity, forensics, infectious disease, oncology and occupational testing. As of Dec 31 2009, Co. had a network of 38 primary laboratories and about 1,500 patient service centers along with a network of branches and STAT laboratories, which are laboratories that have the ability to perform certain routine tests and report the results to the physician immediately.

Data as of 2020-09-12
Market Cap17.115 Billion Shares Outstanding97.4 Million Avg 30-day Volume797.024 Thousand
P/E Ratio49.6 Dividend Yield EPS3.66
Price/Sales1.492 Price cash flow ratio11.1 Price free cash flow ratio18.4
Book Value75.49 Price to Tangible Book-4.48 Alpha-0.01
Short Interest Ratio1.62 % Short Interest to Float1.2 R-squared0.503302
BETA1.69771 52-week High/Low206.74 / 98.02 Stddev0.102249
View SEC Filings from LH instead.
Q2 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 22 13 69.23% 10 (0.65%) 7 (0.45%) 42.86%
Funds Holding: 779 743 4.85% 179 (11.68%) 161 (10.29%) 11.18%
13F shares: 87.857 Million 87.288 Million 0.65% 24.013 Million 23.609 Million 1.71%
% Ownership 90.2019 89.8914 0.35% 24.6545 24.3132 1.4%
New Positions: 128 79 62.03% 46 22 109.09%
Increased Positions 246 267 -7.87% 52 59 -11.86%
Closed Positions 80 112 -28.57% 25 50 -50.0%
Reduced Positions 288 279 3.23% 62 68 -8.82%
Total Calls 841.044 Thousand 927.586 Thousand -9.33% 302 Thousand 103.7 Thousand 191.22%
Total Puts 735.775 Thousand 327.429 Thousand 124.71% 525.5 Thousand 174.5 Thousand 201.15%
PUT/CALL Ratio 0.87 0.35 148.57% 1.74 1.68 3.57%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding LH (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding LH BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

WILKINSON PETER J SVP, CHIEF ACCOUNTING OFFICER

  • Officer
0 2020-08-01 4

WILLIAMS R SANDERS

  • Director
5,095 2020-07-08 3

VAN DER VAART SANDRA D EVP, CHIEF LEGAL OFFICER

  • Officer
4,044 2020-07-02 7

KING DAVID P

  • Director
332,096 2020-05-05 6

KIRCHGRABER PAUL R CEO, COVANCE DRUG DEVELOPMENT

  • Officer
8,087 2020-04-03 7

EISENBERG GLENN A CHIEF FINANCIAL OFFICER, EVP

  • Officer
26,124 2020-03-30 5

BERBERIAN LANCE EVP, CIO & CTO

  • Officer
10,543 2020-03-30 4

SCHROEDER MARK S EVP, PRESIDENT-DIAGNOSTICS LAB

  • Officer
3,213 2020-03-30 6

SUMMY AMY B. EVP, CHIEF MARKETING OFFICER

  • Officer
0 2020-03-02 2

SELTZ JUDITH C EVP, CHRO

  • Officer
580 2020-02-28 3

BELINGARD JEAN-LUC

  • Director
14,682 2020-02-19 4

ANDERSON KERRII B

  • Director
20,360 2020-02-12 3

NEUPERT PETER M

  • Director
9,996 2020-02-12 2

SCHECHTER ADAM H PRESIDENT & CEO

  • Officer
  • Director
7,689 2020-02-12 3

KONG GARHENG

  • Director
8,452 2020-02-12 2

GILLILAND DWIGHT GARY

  • Director
5,766 2020-02-12 2

PARHAM RICHELLE P

  • Director
5,088 2020-02-12 2

CAVENEY BRIAN J EVP, PRESIDENT OF DIAGNOSTICS

  • Officer
2,326 2020-02-12 3

DAVIS JEFFREY A.

  • Director
0 2020-02-04 3

UTHGENANNT LISA J CHIEF HUMAN RESOURCES OFFICER

  • Officer
4,660 2019-09-04 0

MITTELSTAEDT ROBERT E JR

  • Director
15,515 2019-05-09 0

RATLIFF JOHN D CEO, COVANCE DRUG DEVELOPMENT

  • Officer
17,061 2019-04-03 0

DODSON EDWARD T PRINCIPAL ACCOUNTING OFFICER

  • Officer
13,663 2019-04-01 0

EBERTS F SAMUEL III CHIEF LEGAL OFFICER, SECRETARY

  • Officer
28,823 2019-02-12 0

GARY M. HUFF CEO, LABCORP DIAGNOSTICS

  • Officer
1,850 2018-09-04 0

BOYLE JAMES T. JR. EVP,CEO OF LABCORP DIAGNOSTICS

  • Officer
23,454 2016-03-30 0

KELLER DEBORAH L CEO, COVANCE DRUG DEVELOPMENT

  • Officer
19,754 2016-03-11 0

HERRING JOSEPH L CEO OF COVANCE DRUG DIVISION

  • Officer
No longer subject to file 2015-07-31 0

BRECHER MARK E CMO, LABCORP DIAGNOSTICS

  • Officer
5,511 2015-03-30 0

HAYES WILLIAM B CHIEF FINANCIAL OFFICER, EVP

  • Officer
19,400 2014-06-06 0

LANE WENDY E

  • Director
19,388 2014-05-08 0

RUBENSTEIN ARTHUR H

  • Director
11,772 2014-05-08 0

WEIKEL M KEITH

  • Director
13,958 2014-05-07 0

FONSECA LIDIA CHIEF INFORMATION OFFICER

  • Officer
9,087 2013-03-28 0

COLES N ANTHONY

  • Director
2,584 2013-02-15 0

MAC MAHON THOMAS P

  • Director
32,297 2012-09-06 0

WALTON ANDREW SCOTT EVP

  • Officer
22,298 2012-04-09 0

CONRAD ANDREW J EVP, CHIEF SCIENTIFIC OFFICER

  • Officer
32,641 2011-02-09 0

HARDISON DON M EVP

  • Officer
19,928 2009-12-31 0

SMITH BRADFORD T

  • Director
16,030 2009-02-20 0

LAI GOLDMAN MYLA EVP & CHIEF MEDICAL OFFICER

  • Officer
24,991 2008-11-20 0

HAAS WILLIAM EVP, ESOTERIX BUSINESS

  • Officer
0 2008-05-07 0

MILLER BENJAMIN R EVP, SALES & MARKETING

  • Officer
10,135 2008-03-06 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

WILKINSON PETER J - Officer SVP, CHIEF ACCOUNTING OFFICER

2020-08-18 08:20:42 -0400 2020-08-01 A 150 a 2,334 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments